Revive Therapeutics Ltd. Overview
Pro stress-test →Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. The company is pursuing Bucillamine as a treatment for public health emergencies and rare inflammatory disorders, while advancing psilocybin-based therapeutics.
Strategic Profile
Pro stress-test →The Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. In May 2026, Revive provided an update on its DRDC-led study evaluating Bucillamine as a potential nerve agent treatment, with final findings pending authorization.
Competitive Landscape
Pro stress-test →Revive competes in the specialty pharmaceutical and rare disease/public health countermeasure markets. Direct competitors include larger players like Gilead Sciences (infectious disease), Vertex Pharmaceuticals (rare disease), and smaller development-stage companies focusing on psilocybin-assisted therapies and medical countermeasures. Revive's regulatory advantages (FDA designations) and dual-asset approach differentiate it, but minimal scale and resources relative to established biotech players create competitive disadvantages.
Industry Context
Revive Therapeutics Ltd. operates in Specialty pharmaceuticals for rare diseases and medical countermeasures.
Key facts
Founded: Unknown · Headquarters: Toronto, CA · Employees: 2 · Revenue: N/A · Market cap: $15.2M CAD